Lentiviral vectors for gene delivery into cells

DNA and Cell Biology

Volumn 21, Issue 12, 2002, Pages 937-951

  Quinonez, Ricardo ^a   Sutton, Richard E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BETA GLUCURONIDASE; CEREBROSIDE SULFATASE; CYCLIC GMP PHOSPHODIESTERASE BETA; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLOBIN; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 4; LENTIVIRUS VECTOR; LUCIFERASE; NEUBLASTIN; NEUROPROTECTIVE AGENT; PHOSPHODIESTERASE; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VPR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CELL LINE; CELLULAR IMMUNITY; CYTOPATHOGENIC EFFECT; DNA RECOMBINATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; LIVER CELL; MAMMAL CELL; METACHROMATIC LEUKODYSTROPHY; METHODOLOGY; MUCOPOLYSACCHARIDOSIS; MURINE LEUKEMIA VIRUS; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; SAFETY; SICKLE CELL ANEMIA; T LYMPHOCYTE; TARGET CELL; THALASSEMIA; TRANSGENE; TREATMENT INDICATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS DETECTION; VIRUS GENOME; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TYPING;

ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIV; HUMANS; LENTIVIRUS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MAMMALIA; MURINAE; MURINE LEUKEMIA VIRUS; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 0036968555     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454902762053873     Document Type: Review

References (155)

1. ALISKY, J.M., HUGHES, S.M., SAUTER, S.L., et al. (2000). Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 11, 2669-2673.
2. ARYA, S.K., ZAMANI, M., KUNDRA P., et al. (1998). Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging. Hum. Gene Ther. 9, 1371-1380.
3. AZAD, A.A. (2000). Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? Biochem. Biophys. Res. Commun. 267, 677-685.
4. BAINBRIDGE, J.W., STEPHENS, C., PARSLEY, K., et al. (2001). In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8, 1665-1668.
5. BAEK, S.C., LIN, Q., ROBBINS, P.B., et al. (2001). Sustainable systemic delivery via a single injection of lentivirus into human skin tissue. Hum. Gene. Ther. 12, 1551-1558.
6. BATTISTE, J.L., MAO, H., RAO, N.S., et al. (1996). Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science 273, 1547-1551.
7. BENSADOUN, J.C., DEGLON, N., TSENG, J.L., et al. (2000). Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164, 15-24.
8. BERGER, E.A., MURPHY, P.M., and FARBER, J.M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700.
9. BERKOWITZ, R., ILVES, H., LIN, Y., et al. (2001). Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J. Virol. 75, 3371-3382.
10. BLOMER, U., KAFRI, T., et al. (1998). Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. Proc. Natl. Acad. Sci. USA 95, 2603-2608.
11. BLOMER, U., NALDINI, L., KAFRI, T., et al. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-6649.
12. BOCK, P.J., and MARKOVITZ, D.M. (2001). Infection with HIV-2. Aids 15(Suppl 5), S35-45.
13. BOGERD, H.P., FRIDELL, R.A., MADORE, S., et al. (1995). Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 82, 485-494.
14. BROOKS, A.I., STEIN, C.S., HUGHES, S.M., et al. (2002). Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA 99, 6216-6221.
15. BUCHMAN, A.R., and BERG, P. (1988). Comparison of intron-dependent and intron-independent gene expression. Mol. Cell Biol. 8, 4395-4405.
16. BUCHSCHACHER, G.L., Jr., and PANGANIBAN, A.T. (1992). Human immunodeficiency virus vectors for inducible expression of foreign genes. J. Virol. 66, 2731-2739.
17. BUKOVSKY, A.A., SONG, J.P., and NALDINI, L. (1999). Interaction of human immunodeficiency virus-derived vectors with wildtype virus in transduced cells. J. Virol. 73, 7087-7092.
18. BURNS, J.C., FRIEDMANN, T., DRIEVER, W., et al. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037.
19. -) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96, 2988-2993.
20. CHAN, S.Y., SPECK, R.F., MA, M.C., et al. (2000). Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol. 74, 4933-4937.
21. COHEN, E.A., SUBBRAMANIAN, R.A., and GOTTLINGER, H.G. (1996). Role of auxiliary proteins in retroviral morphogenesis. Curr. Top. Microbiol. Immunol. 214, 219-235.
22. COLLINS, K.L., CHEN, B.K., KALAMS, S.A., et al. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401.
23. CONSIGLIO, A., QUATTRINI, A., MARTINO, S., et al. (2001). In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7, 310-316.
24. CORBEAU, P., KRAUS, G., and WONG-STAAL, F. (1996). Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc. Natl. Acad. Sci. USA 93, 14070-14075.
25. CORBEAU, P., KRAUS, G., and WONG-STAAL, F. (1998). Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther. 5, 99-104.
26. CORBEAU, P., and WONG-STAAL, F. (1998). Anti-HIV effects of HIV vectors. Virology 243, 268-274.
27. CULLEN, B.R. (1998). HIV-1 auxiliary proteins: making connections in a dying cell. Cell 93, 685-692.
28. CURRAN, M.A., KAISER, S.M., ACHACOSO, P.L., et al. (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1, 31-38.
29. DARDALHON, V., HERPERS, B., NORAZ, N., et al. (2001). Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther. 8, 190-198.
30. DE NORONHA, C.M., SHERMAN, M.P., LIN, H.W., et al. (2001). Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294, 1105-1108.
31. DENG, H.K., UNUTMAZ, D., KEWALRAMANI, V.N., et al. (1997). Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388, 296-300.
32. DULL, T., ZUFFEREY, R., KELLY, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471.
33. EHRET, A., LI-WEBER, M., FRANK, R., et al. (2001). The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur. J. Immunol. 31, 1790-1799.
34. - cell transduction via lentivirus-based gene transfer vectors. Hum. Gene Ther. 10, 1479-1489.
35. FARSON, D., WITT, R., MCGUINNESS, R., et al. (2001). A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12, 981-997.
36. FISCHER, U., HUBER, U., BOELENS, W.C., et al. (1995). The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82, 475-483.
37. FOUCHIER, R.A., MEYER, B.E., SIMON, J.H., et al. (1998). Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J. Virol. 72, 6004-6013.
38. FRANKEL, A.D., and YOUNG, J.A. (1998). HIV-1: fifteen proteins and an RNA and an RNA. Annu. Rev. Biochem. 67, 1-25.
39. FREEMAN, D.J., LECLERC, I., and RUTTER, G.A. (1999). Present and potential future use of gene therapy for the treatment of non-insulin dependent diabetes mellitus (Review). Int. J. Mol. Med. 4, 585-592.
40. FRITZ, C.C., ZAPP, M.L., and GREEN, M.R. (1995). A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 376, 530-533.
41. FURUTA, R.A., KUBOTA, S., MAKI, M., et al. (1995). Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy. J. Virol. 69, 1591-1599.
42. GALLICHAN, W.S., KAFRI, T., KRAHL, T., et al. (1998). Lentivirusmediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum. Gene Ther. 9, 2717-2726.
43. GELEZIUNAS, R., XU, W., TAKEDA, K., et al. (2001). HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410, 834-838.
44. GEORGIEVSKA, B., KIRIK, D., ROSENBLAD, C., et al. (2002). Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13, 75-82.
45. GEROLAMI, R., UCH, R., JORDIER, F., et al. (2000). Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 7, 1286-1292.
46. GIANNOUKAKIS, N., MI, Z., GAMBOTTO, A., et al. (1999). Infection of intact human islets by a lentiviral vector. Gene Ther. 6, 1545-1551.
47. +) T Cell Activation. Exp. Cell Res. 275, 243-254.
48. GOH, W.C., ROGEL, M.E., KINSEY, C.M., et al. (1998). HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4, 65-71.
49. GOLD, M.O., YANG, X., HERRMANN, C.H., et al. (1998). PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 72, 4448-4453.
50. GONZALEZ, E., PUNZON, C., GONZALEZ, M., et al. (2001). HIV-1 Tat inhibits IL-2 gene transcription through qualitative and quantitative alterations of the cooperative Rel/AP1 complex bound to the CD28RE/AP1 composite element of the IL-2 promoter. J. Immunol. 166, 4560-4569.
51. GUSELLA, G.L., FEDOROVA, E., MARRAS, D., et al. (2002). In vivo gene transfer to kidney by lentiviral vector. Kidney Int. 61(Suppl 1), 32-36.
52. HASSAINE, G., COURCOUL, M., BESSOU, G., et al. (2001). The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. J. Biol. Chem. 276, 16885-16893.
53. HELSETH, E., KOWALSKI, M., GABUZDA, D., et al. (1990). Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol. 64, 2416-2420.
54. HOPE, T.J. (1999). The ins and outs of HIV Rev. Arch. Biochem. Biophys. 366, 186-191.
55. HWANG, J.J., LI, L., and ANDERSON, W.F. (1997). A conditional self-inactivating retrovirus vector that uses a tetracycline-responsive expression system. J. Virol. 71, 7128-7131.
56. INUBUSHI, R., and ADACHI, A. (1999). Cell-dependent function of HIV-1 Vif for virus replication (Review). Int. J. Mol. Med. 3, 473-476.
57. IWAKUMA, T., Y. CUI, and CHANG, L.J. (1999). Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261, 120-132.
58. JOHNSTON, J.C., GASMI, M., LIM, L.E., et al. (1999). Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73, 4991-5000.
59. JONES, K.A., and PETERLIN, B.M. (1994). Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63, 717-743
60. + M phase of the cell cycle. J. Virol. 69, 6304-6313.
61. JU, Q., EDELSTEIN, D., BRENDEL, M.D., et al. (1998). Transduction of non-dividing adult human pancreatic beta cells by an integrating lentiviral vector. Diabetologia 41, 736-739.
62. KAFRI, T., BLOMER, U., PETERSON, D.A., et al. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17, 314-317.
63. KAFRI, T., VAN PRAAG, H., OUYANG, L., et al. (1999). A packaging cell line for lentivirus vectors. J. Virol. 73, 576-584.
64. KALPANA, G.V. (1999). Retroviral vectors for liver-directed gene therapy. Semin. Liver Dis. 19, 27-37.
65. KAMEOKA, M., MORGAN, M., BINETTE, M., et al. (2002). The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. J. Virol. 76, 3637-3645.
66. KAUL, M., YU, H., RON, Y., et al. (1998). Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 249, 167-174.
67. KERKAU, T., BACIK, I., BENNINK, J.R., et al. (1997). The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J. Exp. Med. 185, 1295-1305.
68. KIM, V.N., MITROPHANOUS, K., KINGSMAN, S.M., et al. (1998). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811-816.
69. KINOSHITA, S., CHEN, B.K., KANESHIMA, H., et al. (1998). Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95, 595-604.
70. KLAGES, N., ZUFFEREY, R., and TRONO, D. (2000). A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2, 170-176.
71. KLIMATCHEVA, E., PLANELLES, V., DAY, S.L., et al. (2001). Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol. Ther. 3, 928-939.
72. KOBINGER, G.P., WEINER, D.J., YU, Q.C., et al. (2001). Filoviruspseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19, 225-230.
73. KORDOWER, J.H., BLOCH, J., MA, S.Y., et al. (1999). Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160, 1-16.
74. KORDOWER, J.H., EMBORG, M.E., BLOCH, J., et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
75. LAI, Z., HAN, I., PARK, M., et al. (2002). Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 3651-3656.
76. LAMB, R.A., and PINTO, L.H., (1997). Do Vpu and Vpr of human immunodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life-cycles? Virology 229, 1-11.
77. LANDAU, N.R., PAGE, K.A., and LITTMAN, D.R. (1991). Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J. Virol. 65, 162-169.
78. LI, Y., C. DRONE, SAT, E., et al. (1993). Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. J. Virol. 67, 4070-4077.
79. LOIS, C., HONG, E.J., PEASE, S., et al. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872.
80. LOTERY, A.J., DERKSEN, T.A., RUSSELL, S.R., et al. (2002). Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum. Gene Ther. 13, 689-696.
81. MADANI, N., and KABAT, D. (1998). An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72, 10251-10255.
82. MANGASARIAN, A., FOTI, M., AIKEN, C., et al. (1997). The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Immunity 6, 67-77.
83. MANNINEN, A., and SAKSELA, K. (2002). HIV-1 Nef Interacts with Inositol Trisphosphate Receptor to Activate Calcium Signaling in T Cells. J. Exp. Med. 195, 1023-1032.
84. MARCELLO, A., and GIARETTA, I. (1998). Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector. Res. Virol. 149, 419-431.
85. MARGOTTIN, F., BENICHOU, S., DURAND, H., et al. (1996). Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Virology 223, 381-386.
86. MARGOTTIN, F., BOUR, S.P., DURAND, H., et al. (1998). A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1, 565-574.
87. MAUTINO, M.R., and MORGAN, R.A. (2002a). Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS 16, 11-26.
88. MAUTINO, M.R., and MORGAN, R.A. (2002b). Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 9, 421-431.
89. MAZARAKIS, N.D., AZZOUZ, M., ROHLL, J.B., et al. (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10, 2109-2121.
90. MEYER, B.E., and MALIM, M.H. (1994). The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev. 8, 1538-1547.
91. MILLER, D.G., ADAM, M.A., and MILLER, A.D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10, 4239-4242.
92. MITROPHANOUS, K., YOON, S., ROHLL, J., et al. (1999). Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808-1818.
93. MIYOSHI, H., BLOMER, U., TAKAHASHI, M., et al. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157.
94. MIYOSHI, H., TAKAHASHI, M., GAGE, F.H., et al. (1997). Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94, 10319-10323.
95. MOCHIZUKI, H., SCHWARTZ, J.P., TANAKA, K., et al. (1998). High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72, 8873-8883.
96. MOREAU-GAUDRY, F., XIA, P., JIANG, G., et al. (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98, 2664-2672.
97. MSELLI-LAKHAL, L., FAVIER, C., DA SILVA TEIXEIRA, M.F., et al. (1998). Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. Arch. Virol. 143, 681-695.
98. NALDINI, L., BLOMER, U., GAGE, F.H., et al. (1996a). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93, 11382-11388.
99. NALDINI, L., BLOMER, U., GALLAY, P., et al. (1996b). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
100. NALDINI, L., and VERMA, I.M. (2000). Lentiviral vectors. Adv. Virus Res. 55, 599-609.
101. PACCHIA, A.L., ADELSON, M.E., KAUL, M., et al. (2001). An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282, 77-86.
102. PAGE, K.A., LANDAU, N.R., and LITTMAN, D.R. (1990). Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64, 5270-5276.
103. PANG, S., KANG, M.K., KUNG, S., et al. (2001). Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin. Cancer Res. 7, 3567-3573.
104. PARK, F., OHASHI, K., and KAY, M.A. (2000). Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 96, 1173-1176.
105. PAWLIUK, R., WESTERMAN, K.A., FABRY, M.E., et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368-2371.
106. PENG, K.W., PHAM, L., YE, H., et al. (2001). Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther. 8, 1456-1463.
107. PFEIFER, A., IKAWA, M., DAYN, Y., et al. (2002). Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc. Natl. Acad. Sci. USA 99, 2140-2145.
108. PODSAKOFF, G.M. (2001). Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector. Mol. Ther. 4, 282-283.
109. POESCHLA, E., GILBERT, J., LI, X., et al. (1998). Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J. Virol. 72, 6527-6536.
110. POESCHLA, E.M., WONG-STAAL, F., and LOONEY, D.J. (1998). Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354-357.
111. POLLARD, V.W., and MALIM, M.H. (1998). The HIV-1 Rev protein. Annu. Rev. Microbiol. 52, 491-532.
112. POZNANSKY, M., LEVER, A., BERGERON, L., et al. (1991). Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J. Virol. 65, 532-536.
113. RAMEZANI, A., HAWLEY, T.S., and HAWLEY, R.G. (2000). Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol. Ther. 2, 458-469.
114. RENKEMA, G.H., and SAKSELA, K. (2000). Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci. 5, D268-283.
115. RICHARD, E., MENDEZ, M., MAZURIER, F., et al. (2001). Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol. Ther. 4, 331-338.
116. ROE, T., REYNOLDS, T.C., YU, G., et al. (1993). Integration of murine leukemia virus DNA depends on mitosis. Embo J. 12, 2099-2108.
117. ROMANO, G., MICHELL, P., PACILIO, C., et al. (2000). Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18, 19-39.
118. SADAIE, M.R., ZAMANI, M., WHANG, S., et al. (1998). Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat. J. Med. Virol. 54, 118-128.
119. SHERMAN, M.P., DE NORONHA, C.M., HEUSCH, M.I., et al. (2001). Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J. Virol. 75, 1522-1532.
120. SHICHINOHE, T., BOCHNER, B.H., MIZUTANI, K., et al. (2001). Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 8, 879-889.
121. SIMMONS, A., ALUVIHARE, V., and MCMICHAEL, A. (2001). Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14, 763-777.
122. SIRVEN, A., PFLUMIO, F., ZENNOU, V., et al. (2000). The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96, 4103-4110.
123. +)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol. Ther. 3, 438-448.
124. SOL-FOULON, N., MORIS, A., NOBILE, C., et al. (2002). HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 16, 145-155.
125. SPARACIO, S., PFEIFFER, T., SCHAAL, H., et al. (2001). Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther. 3, 602-612.
126. SRINIVASAKUMAR, N., CHAZAL, N., HELGA-MARIA, C., et al. (1997). The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol. 71, 5841-5848.
127. STEIN, C.S., KANG, Y., SAUTER, S.L., et al. (2001). In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol. Ther. 3, 850-856.
128. STRIPECKE, R., CARDOSO, A.A., PEPPER, K.A., et al. (2000). Lentiviral vectors for efficient delivery of CD80 and granulocytemacrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96, 1317-1326.
129. SUTTON, R.E. (2000). Lentiviral vectors. In Viral Vectors. A. Cid-Arregui and A. Garcia-Carranca, eds. (Biotechniques Books Eaton Publishing, Natick, MA) pp. 485-499.
130. SUTTON, R.E., WU, H.T., RIGG, R., et al. (1998). Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72, 5781-5788.
131. SWANN, S.A., WILLIAMS, M., STORY, C.M., et al. (2001). HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 282, 267-277.
132. TAKAHASHI, M., MIYOSHI, H., VERMA, I.M., et al. (1999). Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J. Virol. 73, 7812-7816.
133. UCHIDA, N., SUTTON, R.E., FRIERA, A.M., et al. (1998). HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 95, 11939-11944.
134. ULLMAN, K.S., POWERS, M.A., and FORBES, D.J. (1997). Nuclear export receptors: from importin to exportin. Cell 90, 967-970.
135. UNUTMAZ, D., KEWALRAMANI, V.N., and LITTMAN, D.R. (1998). G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. Semin. Immunol. 10, 225-236.
136. UNUTMAZ, D., KEWALRAMANI, V.N., MARMON, S., et al. (1999). Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189, 1735-1746.
137. VALENTIN, A., ROSATI, M., PATENAUDE, D.J., et al. (2002). Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 99, 7015-7020.
138. VIGNA, E., and NALDINI, L. (2000). Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2, 308-316.
139. WANG, G., SINN, P.L., and MCCRAY, Jr., P.B. (2000). Development of retroviral vectors for gene transfer to airway epithelia. Curr. Opin. Mol. Ther. 2, 497-506.
140. WANG, G., SLEPUSHKIN, V., ZABNER, J., et al. (1999). Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J. Clin. Invest. 104, R55-62.
141. WEI, C.M., GIBSON, M., SPEAR, P.G., et al. (1981). Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol. 39, 935-944.
142. WEI, P., GARBER, M.E., FANG, S.M., et al. (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451-462.
143. WRZESINSKI, S., SEGUIN, R., LUI, Y., et al. (2000). HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res. Hum. Retroviruses 16, 1771-1776.
144. XU, K., MA, H., MCCOWN, T.J., et al. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104.
145. YAMADA, K., OLSEN, J.C., PATEL, M., et al. (2001). Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. Mol. Ther. 3, 485-490.
146. YANG, X., GOLD, M.O., TANG, D.N., et al. (1997). TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. USA 94, 12331-12336.
147. YANG, X., HERRMANN, C.H., and RICE, A.P. (1996). The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70, 4576-4584.
148. YI, R., BOGERD, H.P., and CULLEN B.R. (2002). Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs. J. Virol. 76, 2036-2042.
149. YU, D., CHEN, D., CHIU, C., et al. (2001). Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 8, 628-635.
150. YU, S.F., VON RUDEN, T., KANTOFF, P.W., et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83, 3194-3198.
151. ZENNOU, V., PETIT, C., GUETARD, D., et al. (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185.
152. ZHANG, Z., SCHULER, T., ZUPANCIC, M., et al. (1999). Sexual transmission and propagation of SIV and HIV in resting and activated CD41 T cells. Science 286, 1353-1357.
153. ZUFFEREY, R., DONELLO, J.E., TRONO, D., et al. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892.
154. ZUFFEREY, R., DULL, T., MANDEL, R.J., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880.
155. ZUFFEREY, R., NAGY, D., MANDEL, R.J., et al. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875.